deaths (OS)

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-47%